BPTH: 74% | Bio-Path Has Initiated A Therapeutic Program To Develop BP1001-A For Obesity And Related Metabolic Diseases, This Program Marks The First Application Of DNAbilize Technology For Development Of A Non-cancer Application

DOCU: 6% | DocuSign shares are trading higher after it was announced the company will join the S&P MidCap 400.

SAGE: -26% | Sage Therapeutics shares are trading lower after the company stops further development of dalzanemdor in Alzheimer's Disease following disappointing results from the Phase 2 LIGHTWAVE Study.